Among the 13 CAR-T therapeutics that have received regulatory approval are Gilead’s Yescarta and Immuneel Therapeutics’ ...

The CAR-T landscape is dominated by blood cancers, which account for more than half of all CAR-Ts in the active pipeline and make up nine out of the top 10 CAR-T indications. Industry leaders such ...

▪ If you decide to draw your own landscape plan, draw it to scale. Draw in all the permanent features like the walks, fences, ...

Bristol Myers Squibb remains the dominant player in the CAR-T landscape with two already marketed products—Abecma (idecabtagene vicleucel) for multiple myeloma and Breyanzi (lisocabtagene ...

The gist of this is that the technology, if deployed with clinical success, would disrupt the CAR-T landscape. I will be going over several reasons why below, but the promise of this is another ...

A full VIN check guarantees that you are aware of the car's history, and that enables you to make a safe and solid investment ...

These factors collectively create a high bar for market entry and commercial success in the competitive CAR T landscape. The FDA’s decision to remove staggered dosing requirements could ...

IndyCar team owners see rising expenses as the sport weighs changes to its racecars. It has led to more questions than ...

What challenges does Adicet face in the competitive CAR-T landscape? Adicet Bio faces significant challenges in the competitive CAR-T landscape. The field is crowded with both established players and ...

In-car displays are growing in size and number—even taking over windscreens—as technology and competition continue to reshape the cabin experience.